Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Short Interest Update

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY – Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totaling 2,735 shares, a decrease of 86.4% from the April 30th total of 20,045 shares. Based on an average daily volume of 70,370 shares, the short-interest ratio is presently 0.0 days. Currently, 0.5% of the shares of the stock are short sold.

Sigyn Therapeutics Stock Down 7.9%

Shares of OTCMKTS SIGY traded down $0.00 during trading on Friday, reaching $0.04. The company had a trading volume of 30,000 shares, compared to its average volume of 114,341. The company’s fifty day moving average price is $0.04 and its 200-day moving average price is $0.73. Sigyn Therapeutics has a 12 month low of $0.01 and a 12 month high of $5.00. The stock has a market cap of $88,900.00 and a P/E ratio of -0.01.

Get Sigyn Therapeutics alerts:

About Sigyn Therapeutics

(Get Free Report)

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.

Further Reading

• Five stocks we like better than Sigyn Therapeutics
• Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
• Salesforce Stock Finds Support as AI Momentum Builds
• Dollar Tree Keeps Winning After Family Dollar Divorce
• Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet

Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.